Publications

Detailed Information

Seroprevalence rate after one dose of varicella vaccine in infants

DC Field Value Language
dc.contributor.authorKim, So Hee-
dc.contributor.authorLee, Hoan Jong-
dc.contributor.authorPark, Su Eun-
dc.contributor.authorOh, Sung Hee-
dc.contributor.authorChoi, Eun Hwa-
dc.contributor.authorLee, Seong Yeon-
dc.date.accessioned2012-06-12T04:52:56Z-
dc.date.available2012-06-12T04:52:56Z-
dc.date.issued2010-07-
dc.identifier.citationJOURNAL OF INFECTION; Vol.61 1; 66-72ko_KR
dc.identifier.issn0163-4453-
dc.identifier.urihttps://hdl.handle.net/10371/77000-
dc.description.abstractBackground: Live, attenuated varicella vaccine has been used since 1988 in Korea. However, varicella is still prevalent among both vaccinated and unvaccinated individuals, despite a relatively high level of immunization rate up to 80%. A recent report has demonstrated similar to 20% of primary vaccine failure rate after one dose of varicella vaccine using the fluorescent antibody to membrane antigen (FAMA) assay. Methods: The seroprevalence rate was determined using the FAMA and ELISA assays in 67 Korean infants following one dose of varicella vaccine. Positive fluorescence at a serum dilution of 1: 4 or greater was considered as seropositive. Results: The median age at vaccination was 12 months and the post-immunization sera were obtained on average 6.3 months (range 6 weeks-12 months) after vaccination. Among the 67 vaccinated infants, 56 (83.6%) were seropositive by FAMA assay while 30 (44.8%) were seropositive by ELISA. The geometric mean titers (GMTs) of the seropositive vaccinated infants (n = 56) were significantly lower than the GMTs of 9 individuals with a history of varicella (1:17.0 vs. 1:74.7, P = 0.001). Although there were no significant differences in seropositive rates according to intervals, there was a decreasing trend in the GMTs over time among the 56 seropositive recipients (r(2) = 0.154, P < 0.001). Conclusions: These data can be useful for optimizing the immunization strategy against varicella and should be confirmed by a prospective study including a large number of immunized infants. (c) 2010 The British Infection Society. Published by Elsevier Ltd. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherW B SAUNDERS CO LTDko_KR
dc.subjectVaricella vaccineko_KR
dc.subjectFluorescent antibody to membrane antigenko_KR
dc.subjectSeroprevalenceko_KR
dc.titleSeroprevalence rate after one dose of varicella vaccine in infantsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김소희-
dc.contributor.AlternativeAuthor이환종-
dc.contributor.AlternativeAuthor박수은-
dc.contributor.AlternativeAuthor오성희-
dc.contributor.AlternativeAuthor이성연-
dc.contributor.AlternativeAuthor최은화-
dc.identifier.doi10.1016/j.jinf.2010.04.001-
dc.citation.journaltitleJOURNAL OF INFECTION-
dc.description.citedreferenceMarin M, 2008, PEDIATRICS, V122, pE744, DOI 10.1542/peds.2008-0567-
dc.description.citedreferenceMichalik DE, 2008, J INFECT DIS, V197, P944, DOI 10.1086/529043-
dc.description.citedreferenceSadzot-Delvaux C, 2008, J INFECT DIS, V197, pS185, DOI 10.1086/522163-
dc.description.citedreferenceMacartney KK, 2008, J INFECT DIS, V197, pS191, DOI 10.1086/522157-
dc.description.citedreferenceSeward JF, 2008, J INFECT DIS, V197, pS82, DOI 10.1086/522145-
dc.description.citedreferenceStorlie J, 2008, J INFECT DIS, V197, pS49, DOI 10.1086/522127-
dc.description.citedreferenceCHOI EH, 2008, KOREAN J PEDIAT INFE, V15, P12-
dc.description.citedreferenceChaves SS, 2007, NEW ENGL J MED, V356, P1121-
dc.description.citedreference*CDCP, 2007, MMWR-MORBID MORTAL W, V56, P1-
dc.description.citedreferenceCOHEN JI, 2007, FIELDS VIROLOGY, P2773-
dc.description.citedreferenceLEE HG, 2007, 57 ANN FALL M KOR PE, P90-
dc.description.citedreferenceZhou FJ, 2005, JAMA-J AM MED ASSOC, V294, P797-
dc.description.citedreferenceNguyen HQ, 2005, NEW ENGL J MED, V352, P450, DOI 10.1056/NEJMoa042271-
dc.description.citedreferenceDavis MM, 2004, PEDIATRICS, V114, P786, DOI 10.1542/peds.2004-0012-
dc.description.citedreferenceVazquez M, 2004, JAMA-J AM MED ASSOC, V291, P851-
dc.description.citedreferenceKuter B, 2004, PEDIATR INFECT DIS J, V23, P132-
dc.description.citedreferenceGERSHON AA, 2004, VACCINES, P783-
dc.description.citedreference*WHO, 2003, IMM VACC BIOL VAR VA-
dc.description.citedreferenceLau YL, 2002, VACCINE, V20, P2942-
dc.description.citedreferenceLi S, 2002, PEDIATR INFECT DIS J, V21, P337-
dc.description.citedreferenceSeward JF, 2002, JAMA-J AM MED ASSOC, V287, P606-
dc.description.citedreferenceSaiman L, 2001, INFECT CONT HOSP EP, V22, P279-
dc.description.citedreferenceVazquez M, 2001, NEW ENGL J MED, V344, P955, DOI 10.1056/NEJM200103293441302-
dc.description.citedreferenceKANG JH, 1997, KOREAN J PEDIAT INFE, V4, P257-
dc.description.citedreferenceKrah DL, 1996, INFECT DIS CLIN N AM, V10, P507-
dc.description.citedreference*CDCP, 1996, MMWR-MORBID MORTAL W, V45, P1-
dc.description.citedreferenceKRAUSE PR, 1995, J PEDIATR, V127, P518-
dc.description.citedreferenceWATSON B, 1995, J INFECT DIS, V172, P217-
dc.description.citedreferenceWATSON B, 1995, CLIN INFECT DIS, V20, P316-
dc.description.citedreferenceGERSHON A, 1994, CLIN DIAGN VIROL, V2, P271-
dc.description.citedreferenceSOHN YM, 1994, J KOREAN PEDIAT SOC, V37, P1405-
dc.description.citedreferenceSTEINBERG SP, 1991, J CLIN MICROBIOL, V29, P1527-
dc.description.citedreferenceWHITE CJ, 1991, PEDIATRICS, V87, P604-
dc.description.citedreferencePROVOST PJ, 1991, VACCINE, V9, P111-
dc.description.citedreferenceLARUSSA P, 1987, J CLIN MICROBIOL, V25, P2059-
dc.description.citedreferenceBOGGERGOREN S, 1982, J INFECT DIS, V146, P260-
dc.description.citedreferenceTAKAHASH.M, 1974, LANCET, V2, P1288-
dc.description.citedreferenceWILLIAMS V, 1974, J INFECT DIS, V130, P669-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share